ELV: Q2 outperformed expectations, 2026 EPS guidance raised, and broad-based growth drivers affirmed
Second quarter results exceeded expectations, prompting a raise in 2026 EPS guidance to at least $27 and reaffirming confidence in at least 12% EPS growth for 2027. Medicaid remains challenging but manageable, with targeted market exits and prudent margin outlook, while Medicare Advantage, Commerci…